Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:354:181-95.
doi: 10.1007/82_2011_122.

Mucosal vaccines for biodefense

Affiliations
Review

Mucosal vaccines for biodefense

N J Mantis et al. Curr Top Microbiol Immunol. 2012.

Abstract

Bioterrorism is the deliberate release of biological toxins, pathogenic viruses, bacteria, parasites, or other infectious agents into the public sphere with the objective of causing panic, illness, and/or death on a local, regional, or possibly national scale. The list of potential biological agents compiled by the Centers for Disease Control and Prevention is long and diverse. However, a trait common to virtually all the potential bioterrorism agents is the fact that they are likely to be disseminated by either aerosol or in food/water supplies with the intention of targeting the mucosal surfaces of the respiratory or gastrointestinal tracts, respectively. In some instances, inhalation or ingestion would mimic the natural route by which humans are exposed to these agents. In other instances, (e.g., the inhalation of a toxin is normally associated with food borne illness), it would represent an unnatural route of exposure. For most potential bioterrorism agents, the respiratory or gastrointestinal mucosa may simply serve as a route of entry by which they gain access to the systemic compartment where intoxication/replication occurs. For others, however, the respiratory or gastrointestinal mucosa is the primary tissue associated with pathogenesis, and therefore, the tissue for which countermeasures must be developed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Locations of NIAID-Sponsored Regional and National Biodefense Laboratories in the United States. Image from www3.niaid.nih.gov/LabsAndResources/resources/dmid/NBL_RBL/site.htm
Fig. 2
Fig. 2
Class III biological safety cabinets for biodefense research available at RBLs. The NIAID-sponsored RBLs provide full containment for infectious aerosol challenge studies with primates, as well as instrumentation for specialized bioaerosol characterization studies

Similar articles

Cited by

References

    1. Anderson GW, Jr, Leary SE, Williamson ED, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun. 1996;64:4580–4585. - PMC - PubMed
    1. Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol. 2008;18:217–231. doi: 10.1002/rmv.571. - DOI - PubMed
    1. Bergdoll MS. Enterotoxins. In: Easmon CSF, Adlam C, editors. Staphylococci and staphylococcal infections, vol 2. New York: Academic Press; 1983.
    1. Bramwell VW, Eyles JE, Oya Alpar H. Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev. 2005;57:1247–1265. doi: 10.1016/j.addr.2005.01.010. - DOI - PubMed
    1. Cornelius C, Quenee L, Anderson D, et al. Protective immunity against plague. Adv Exp Med Biol. 2007;603:415–424. doi: 10.1007/978-0-387-72124-8_38. - DOI - PubMed

Publication types